Search Results 91-100 of 317 for ✍데이터기반 80211AC 성능저하가없다✍

  1. Cardiovascular Medicine - Clinical trials

    The purpose of this study is to establish a registry that will address the data gap regarding the course of NSTEMI (Non-ST-Elevation Myocardial Infarction) ...

  2. A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure - Mayo Clinic

    A randomized, double-blinded, placebo-controlled study of continuous 6-hour IV infusions of CXL-1427 in hospitalized patients with systolic heart failure.

  3. Efficacy of KL1333 in adult patients with primary mitochondrial disease - Mayo Clinic

    About this study. The purpose of this study is to evaluate efficacy of the study drug on fatigue symptoms, impacts on daily living, lower extremity strength ...

  4. Neurology - Clinical trials

    Rochester, Minn. This is a study to generate feasibilty data regarding the collection of health and psychosocial outcomes after acquired spinal cord injury (SCI) ...

  5. Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE) - Mayo Clinic

    Have at least 4 weeks of reliably and consistently completed baseline seizure diary data. Being treated with at least 1 other ASM, but no more than 4 ASMs ...

  6. A Study to Assess the Effectiveness and Safety of Ublituximab in combination with Umbralisib and Venetoclax (U2-V) Compared to Ublituximab and Umbralisib (U2) in Subjects with Chronic Lymphocytic Leukemia (CLL) - Mayo Clinic

    Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

  7. Elevate CLL R/R: Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia - Mayo Clinic

    This study is designed to evaluate PFS endpoint for acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia. Participation eligibility.

  8. Publications - Amy C. Clayton, M.D. - Mayo Clinic

    DeJong SR, Bakkum-Gamez JN, Clayton AC, Henry MR, Keeney GL, Zhang J, Kroneman TN, Laughlin-Tommaso SK, Ahlberg LJ, VanOosten AL, Weaver AL, Wentzensen N, ...

  9. Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss - Mayo Clinic

    The purpose of this study is to determine the maximum tolerated dose (MTD) of AG-270 and characterize its dose-limiting toxicities (DLTs) when given daily by ...

  10. A Study of AG-946 in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS) - Mayo Clinic

    The purpose of phase 2a is to establish proof-of-concept (POC) for AG-946 in participants with lower-risk myelodysplastic syndromes (LR-MDS) and to evaluate the ...